As drugmakers raise the price of insulin drugs, pharmacy benefit managers are opting to cover less expensive, clinically effective, options for patients. “Employers, unions and government programs that offer these benefits don’t have much choice but to spend their resources on competitively priced (medications) that offer the same or better value,” said Pharmaceutical Care Management Association President and CEO Mark Merritt.